1 / 5

Bedside Sensory Testing

Bedside Sensory Testing. A set of standardized procedures using standardized equipment to conduct basic sensory testing with minimum cost and patient burden ‘Kits’ have been developed and partially validated with procedures and equipment for osteoarthritis (OA) and post-herpetic neuralgia (PHN).

kata
Télécharger la présentation

Bedside Sensory Testing

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Bedside Sensory Testing • A set of standardized procedures using standardized equipment to conduct basic sensory testing with minimum cost and patient burden • ‘Kits’ have been developed and partially validated with procedures and equipment for osteoarthritis (OA) and post-herpetic neuralgia (PHN)

  2. BST Procedures • Local pressure pain threshold (PPT) • Distal PPT • Cold allodyia • Mechanoreceptive function (light touch threshold; LTT) • Tourniquet test (for diffuse noxious inhibitory control; DNIC) PHN only • Punctate hyperalgesia • Dynamic mechanical allodynia • Temporal summation (wind-up)

  3. Can DNIC predict analgesic efficacy of naproxen? P<.001 SES=.77 P<.001 SES=.43 P<.05 SES=.34 OA subjects with dysfunctional DNIC showed greater discrimination of naproxen from placebo. Consistent with Yarnitsky’s (2012) report that poor DNIC function predicted response to duloxetine in PHN.

  4. Can DNIC predict analgesic efficacy of milnacipran? P<.001 P<.001 P<.001 OA subjects’ DNIC made no difference in open-label treatment with milnacipran (double-blind period showed no efficacy net vs. placebo either)

  5. Value of Standardized BST • Variation in sensory testing procedures increases error. Solution: standardization • Many new treatments only demonstrate superiority in a sub-population. Solution: identify mechanisms for targeted treatment • RPC study underway using BST with PHN • Different tests in the BST toolbox may predict efficacy of different treatments in different populations

More Related